BIOFAR – Trademark Portfolio

Entity Type: 99

BIOFAR holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 32 (Light Beverages) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include BIOFAR, LIPOSUC, and NIGHT FEVER. The owner is based in F-92000 NANTERRE.

6, rue des Marguerites

F-92000 NANTERRE , FR

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BIOFAR's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

32
Light Beverages (1 filing)

Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages

29
Meats & Processed Foods (1 filing)

Meat, fish, poultry and game; meat extracts; preserved, frozen, dried and cooked fruits

Frequently Asked Questions

How many trademarks does BIOFAR have?

BIOFAR has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does BIOFAR file in?

BIOFAR files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 32 (Light Beverages), Class 29 (Meats & Processed Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BIOFAR's most well-known trademarks?

BIOFAR's registered trademark portfolio includes well-known marks such as BIOFAR, LIPOSUC, and NIGHT FEVER. These are among 3 currently registered trademarks in the portfolio.

What is BIOFAR's trademark registration success rate?

BIOFAR has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.